APA (7th ed.) Citation

Riedemann, N. C., Wehling, C., & Kirschfink, M. (2017). Controlling the anaphylatoxin C5a in diseases requires a specifically targeted inhibition. Clinical immunology, 180, . https://doi.org/10.1016/j.clim.2017.03.012

Chicago Style (17th ed.) Citation

Riedemann, Niels Christoph, Cyrill Wehling, and Michael Kirschfink. "Controlling the Anaphylatoxin C5a in Diseases Requires a Specifically Targeted Inhibition." Clinical Immunology 180 (2017). https://doi.org/10.1016/j.clim.2017.03.012.

MLA (9th ed.) Citation

Riedemann, Niels Christoph, et al. "Controlling the Anaphylatoxin C5a in Diseases Requires a Specifically Targeted Inhibition." Clinical Immunology, vol. 180, 2017, https://doi.org/10.1016/j.clim.2017.03.012.